Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment

Molecular Medicine

Volumn 6, Issue 10, 2000, Pages 849-866

  Huang, Lili ^a,b   Pardee, Arthur B ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis regulating Proteins; Gelsolin; Hematopoietic Tumor Cells; Hybrid Polar Compounds (HPCs); Suberoylanilide Hydroxamic Acid

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; ENZYME INHIBITOR; HYDROXAMIC ACID; PRIMER DNA; VORINOSTAT;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CULTURE; CELL CYCLE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CASPASES; CELL CYCLE; CELL DIVISION; DNA PRIMERS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; UP-REGULATION;

MLCS; MLOWN;

EID: 0034297220     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.1007/BF03401823     Document Type: Article

References (90)

1. G.N. Hortobagyi Drug therapy—treatment of breast cancer N. Engl. J. Med. 1998 339 974 984 10.1056/NEJM199810013391407 1:CAS:528:DyaK1cXmslCitrY%3D 9753714
2. E.E. Holdener W. Bollag Retinoids Curr. Opin. Oncol. 1993 5 1059 1066 10.1097/00001622-199311000-00019 1:STN:280:DyaK2c7jslygtg%3D%3D 8305540
3. G.T. Budd P.C. Adamson M. Gupta et al. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer Clin. Cancer Res. 1998 4 635 642 9533531 1:CAS:528:DyaK1cXit1aqurY%3D
4. V.M. Richon Y. Webb R. Merger et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation Proc. Natl. Acad. Sci. U.S.A. 1996 93 5705 5708 10.1073/pnas.93.12.5705 1:CAS:528:DyaK28Xjs1Kqtbc%3D 8650156 39124
5. V.M. Richon P. Russo P.G. Venta C.C. Cordon R.A. Rifkind P.A. Marks Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells Cancer Res. 1997 57 2789 2798 9205091 1:CAS:528:DyaK2sXktlSmsr8%3D
6. D.S. Siegel X. Zhang R. Feinman et al. Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells Proc. Natl. Acad. Sci. U.S.A. 1998 95 162 166 10.1073/pnas.95.1.162 1:CAS:528:DyaK1cXjtlyqsQ%3D%3D 9419346 18160
7. M. Andreeff R. Stone J. Michaeli et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent Blood 1992 80 2604 2609 1421378 1:STN:280:DyaK3s%2Fktlejuw%3D%3D
8. J.A. Vrana R.H. Decker C.R. Johnson et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 Oncogene 1999 18 7016 7025 10.1038/sj.onc.1203176 1:CAS:528:DC%2BD3cXhslaqsw%3D%3D 10597302
9. L.A. Cohen S. Amin P.A. Marks R.A. Rifkind D. Desai V.M. Richon Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA) Anticancer Res. 1999 19 4999 5005 10697502 1:CAS:528:DC%2BD3cXhsFais7o%3D
10. L.A. Cohen S. Amin P.A. Marks R.A. Rifkind D. Desai V.M. Richon Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiating agent, suberanilohydroxamic acid (SAHA) Anticancer Res. 1999 19 4999 5005 10697502 1:CAS:528:DC%2BD3cXhsFais7o%3D
11. V.M. Richon S. Emiliani E. Verdin et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Proc. Natl. Acad. Sci. U.S.A. 1998 95 3003 3007 10.1073/pnas.95.6.3003 1:CAS:528:DyaK1cXitV2itro%3D 9501205 19684
12. M. Yoshida M. Kijima M. Akita T. Beppu Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A J. Biol. Chem. 1990 265 17174 17179 2211619 1:CAS:528:DyaK3cXlvVyqsrY%3D
13. M.S. Finnin J.R. Donigian A. Cohen et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999 401 188 193 10.1038/43710 1:CAS:528:DyaK1MXlvFKgtrc%3D 10490031
14. K. Struhl Histone acetylation and transcriptional regulatory mechanisms Genes Dev. 1998 12 599 606 10.1101/gad.12.5.599 1:CAS:528:DyaK1cXitVegu74%3D 9499396
15. A.P. Wolffe Transcriptional control. Sinful repression Nature 1997 387 16 17 10.1038/387016a0 1:CAS:528:DyaK2sXivFOku70%3D 9139815
16. M.J. Pazin J.T. Kadonaga What’s up and down with histone deacetylation and transcription? Cell 1997 89 325 328 10.1016/S0092-8674(00)80211-1 1:CAS:528:DyaK2sXjtFWisLY%3D 9150131
17. J. Torchia C. Glass M.G. Rosenfeld Co-activators and co-repressors in the integration of transcriptional responses Curr. Opin. Cell Biol. 1998 10 373 383 10.1016/S0955-0674(98)80014-8 1:CAS:528:DyaK1cXjvFeltLY%3D 9640539
18. J.L. Magnaghi R. Groisman I. Naguibneva et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase Nature 1998 391 601 605 10.1038/35410 1:CAS:528:DyaK1cXhtVSrs7k%3D
19. A. Brehm E.A. Miska D.J. McCance J.L. Reid A.J. Bannister T. Kouzarides Retinoblastoma protein recruits histone deacetylase to repress transcription Nature 1998 391 597 601 10.1038/35404 1:CAS:528:DyaK1cXhtVSltLg%3D 9468139
20. C.A. Hassig T.C. Fleischer A.N. Billin S.L. Schreiber D.E. Ayer Histone deacetylase activity is required for full transcriptional repression by mSin3A Cell 1997 89 341 347 10.1016/S0092-8674(00)80214-7 1:CAS:528:DyaK2sXjtFWisbs%3D 9150133
21. C.D. Laherty W.M. Yang J.M. Sun J.R. Davie E. Seto R.N. Eisenman Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression Cell 1997 89 349 356 10.1016/S0092-8674(00)80215-9 1:CAS:528:DyaK2sXjtFWmsb4%3D 9150134
22. R.P. Warrell L.Z. He V. Richon E. Calleja P.P. Pandolfi Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase J. Natl. Cancer Inst. 1998 90 1621 1625 10.1093/jnci/90.21.1621 1:CAS:528:DyaK1cXnsVCgt7k%3D 9811311
23. R.J. Lin L. Nagy S. Inoue W. Shao W.J. Miller R.M. Evans Role of the histone deacetylase complex in acute promyelocytic leukaemia Nature 1998 391 811 814 10.1038/35895 1:CAS:528:DyaK1cXhtlCisr4%3D 9486654
24. F. Grignani M.S. De C. Nervi et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia Nature 1998 391 815 818 10.1038/35901 1:CAS:528:DyaK1cXhtlCisrs%3D 9486655
25. L.Z. He F. Guidez C. Tribioli et al. Distinct interactions of PML-RARalpha and PLZF-RAR-alpha with co-repressors determine differential responses to RA in APL Nat. Genet. 1998 18 126 135 10.1038/ng0298-126 1:CAS:528:DyaK1cXosFOrsw%3D%3D 9462740
26. E.S. Alnemri D.J. Livingston D.W. Nicholson et al. Human ICE/CED-3 protease nomenclature Cell 1996 87 171 10.1016/S0092-8674(00)81334-3 1:CAS:528:DyaK28XmsVGhs7k%3D 8861900
27. G.S. Salvesen V.M. Dixit Caspases: intracellular signaling by proteolysis Cell 1997 91 443 446 10.1016/S0092-8674(00)80430-4 1:CAS:528:DyaK2sXnsFGmtLg%3D 9390553
28. S.H. Kaufmann S. Desnoyers Y. Ottaviano N.E. Davidson G.G. Poirier Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis Cancer Res. 1993 53 3976 3985 8358726 1:CAS:528:DyaK3sXmtFKqsro%3D
29. Y.A. Lazebnik S.H. Kaufmann S. Desnoyers G.G. Poirier W.C. Earnshaw Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE Nature 1994 371 346 347 10.1038/371346a0 1:STN:280:DyaK2czns1yktA%3D%3D 8090205
30. S. Bates K.H. Vousden p53 in signaling checkpoint arrest or apoptosis Curr. Opin. Genet. Dev. 1996 6 12 18 10.1016/S0959-437X(96)90004-0 1:CAS:528:DyaK28XhtVWgtL4%3D 8791489
31. P.M. O’Connor J. Jackman I. Bae et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents Cancer Res. 1997 57 4285 4300 9331090
32. J.W. Harper G.R. Adami N. Wei K. Keyomarsi S.J. Elledge The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 1993 75 805 816 10.1016/0092-8674(93)90499-G 1:CAS:528:DyaK2cXhtVShsLk%3D 8242751
33. V. Dulic W.K. Kaufmann S.J. Wilson et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest Cell 1994 76 1013 1023 10.1016/0092-8674(94)90379-4 1:CAS:528:DyaK2cXitl2hs7k%3D 8137420
34. J.Y. Kato M. Matsuoka K. Polyak J. Massague C.J. Sherr Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation Cell 1994 79 487 496 10.1016/0092-8674(94)90257-7 1:CAS:528:DyaK2MXhvFWhsr0%3D 7954814
35. H. Toyoshima T. Hunter p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 Cell 1994 78 67 74 10.1016/0092-8674(94)90573-8 1:CAS:528:DyaK2cXmsVOmurw%3D 8033213
36. J.C. Reed Bcl-2 and the regulation of programmed cell death J. Cell Biol. 1994 124 1 6 10.1083/jcb.124.1.1 1:CAS:528:DyaK2cXntl2mtA%3D%3D 8294493
37. S.J. Korsmeyer Regulators of cell death Trends Genet. 1995 11 101 105 10.1016/S0168-9525(00)89010-1 1:CAS:528:DyaK2MXksVCksL0%3D 7732571
38. R.A. Weinberg The retinoblastoma protein and cell cycle control Cell 1995 81 323 330 10.1016/0092-8674(95)90385-2 1:CAS:528:DyaK2MXlsFSrs7k%3D 7736585
39. A. Almasan Y. Yin R.E. Kelly et al. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis Proc. Natl. Acad. Sci. USA 1995 92 5436 5440 10.1073/pnas.92.12.5436 1:CAS:528:DyaK2MXmtFOgsr8%3D 7777526 41709
40. R.U. Janicke P.A. Walker X.Y. Lin A.G. Porter Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis EMBO J. 1996 15 6969 6978 9003773 452523 1:CAS:528:DyaK2sXosFCitw%3D%3D 10.1002/j.1460-2075.1996.tb01089.x
41. F.M. Hahn J.W. Xuan A.F. Chambers C.D. Poulter Human isopentenyl diphosphate: di-methylallyl diphosphate isomerase: overproduction, purification, and characterization Arch. Biochem. Biophys. 1996 332 30 34 10.1006/abbi.1996.0312 1:CAS:528:DyaK28XkvVGjt7k%3D 8806705
42. J.W. Xuan J. Kowalski A.F. Chambers D.T. Denhardt A human promyelocyte mRNA transiently induced by TPA is homologous to yeast IPP isomerase Genomics 1994 20 129 131 10.1006/geno.1994.1139 1:CAS:528:DyaK2cXlvF2gtrk%3D 8020941
43. K.S. Chen H.F. DeLuca Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3 Biochim. Biophys. Acta 1994 1219 26 32 10.1016/0167-4781(94)90242-9 1:CAS:528:DyaK2MXmvFCgtA%3D%3D 8086474
44. A. Nishiyama M. Matsui S. Iwata et al. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression J. Biol. Chem. 1999 274 21645 21650 10.1074/jbc.274.31.21645 1:CAS:528:DyaK1MXltVymsL4%3D 10419473
45. S. Fujii Y. Nanbu H. Nonogaki et al. Co-expression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium Cancer 1991 68 1583 1591 10.1002/1097-0142(19911001)68:7<1583::AID-CNCR2820680720>3.0.CO;2-N 1:CAS:528:DyaK38Xitlaru70%3D 1654198
46. H. Nakamura H. Masutani Y. Tagaya et al. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma Cancer 1992 69 2091 2097 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X 1:CAS:528:DyaK38Xit1yqtL8%3D 1311982
47. M. Berggren A. Gallegos J.R. Gasdaska P.Y. Gasdaska J. Warneke G. Powis Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia Anticancer Res. 1996 16 3459 3466 9042207 1:CAS:528:DyaK2sXhs1yltrk%3D
48. N. Wakasugi Y. Tagaya H. Wakasugi et al. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2 Proc. Natl. Acad. Sci. U.S.A. 1990 87 8282 8286 10.1073/pnas.87.21.8282 1:CAS:528:DyaK3MXks1Cl 2172979 54939
49. J.R. Gasdaska M. Berggren G. Powis Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism Cell Growth Differ. 1995 6 1643 1650 9019170 1:CAS:528:DyaK2MXpvVCgtbg%3D
50. A. Gallegos J.R. Gasdaska C.W. Taylor et al. Transfection with human thioredoxin increases cell proliferation and a dominantnegative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells Cancer Res. 1996 56 5765 5770 8971189 1:CAS:528:DyaK2sXjsVWi
51. M. Tanaka L. Mullauer Y. Ogiso et al. Gelsolin: a candidate for suppressor of human bladder cancer Cancer Res. 1995 55 3228 3232 7614452 1:CAS:528:DyaK2MXnt1ans7o%3D
52. H.L. Asch K. Head Y. Dong et al. Widespread loss of gelsolin in breast cancers of humans, mice, and rats Cancer Res. 1996 56 4841 4845 8895730 1:CAS:528:DyaK28XmsFygsLY%3D
53. A.H. Dosaka F. Hommura H. Fujita et al. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers Cancer Res. 1998 58 322 327
54. H.K. Lee D. Driscoll H. Asch B. Asch P.J. Zhang Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate Prostate 1999 40 14 19 10.1002/(SICI)1097-0045(19990615)40:1<14::AID-PROS2>3.0.CO;2-6 1:STN:280:DyaK1M3nsVGitA%3D%3D 10344719
55. H.L. Asch J.S. Winston S.B. Edge P.C. Stomper B.B. Asch Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion Breast Cancer Res. Treat. 1999 55 179 188 10.1023/A:1006203632228 1:STN:280:DyaK1MvgvFKksw%3D%3D 10481945
56. Y. Dong H.L. Asch D. Medina et al. Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers Int. J. Cancer 1999 81 930 938 10.1002/(SICI)1097-0215(19990611)81:6<930::AID-IJC15>3.0.CO;2-A 1:CAS:528:DyaK1MXktVanu7Y%3D 10362141
57. L.M. Mielnicki A.M. Ying K.L. Head H.L. Asch B.B. Asch Epigenetic regulation of gelsolin expression in human breast cancer cells Exp. Cell Res. 1999 249 161 176 10.1006/excr.1999.4461 1:CAS:528:DyaK1MXivFOku7c%3D 10328963
58. S.B. Schwartz P.J. Higgins A.K. Rajasekaran C.L. Staiano Gelsolin expression in normal human keratinocytes is a function of induced differentiation Adv. Exp. Med. Biol. 1994 358 169 181 10.1007/978-1-4615-2578-3_16 1:CAS:528:DyaK2MXktVWqtb0%3D 7801803
59. E. Olsen H.H. Rasmussen J.E. Celis Identification of proteins that are abnormally regulated in differentiated cultured human keratinocytes Electrophoresis 1995 16 2241 2248 10.1002/elps.11501601356 1:CAS:528:DyaK28Xks1CnsQ%3D%3D 8824783
60. C.W. Dieffenbach D.N. SenGupta D. Krause D. Sawzak R.H. Silverman Cloning of murine gelsolin and its regulation during differentiation of embryonal carcinoma cells J. Biol. Chem. 1989 264 13281 13288 2546951 1:CAS:528:DyaK3cXhvFart7k%3D
61. L. Qiu M.J. Kelso C. Hansen M.L. West D.P. Fairlie P.G. Parsons Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate Br. J. Cancer 1999 80 1252 1258 10.1038/sj.bjc.6690493 1:CAS:528:DyaK1MXkt1Cltrw%3D 10376979 2362353
62. V.M. Richon R.A. Rifkind P.A. Marks Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells Cell Growth Differ. 1992 3 413 420 1419904 1:CAS:528:DyaK3sXmsVKls7c%3D
63. D.W. Nicholson N.A. Thornberry Caspases: killer proteases Trends Biochem. Sci. 1997 22 299 306 10.1016/S0968-0004(97)01085-2 1:CAS:528:DyaK2sXlsF2jsbY%3D 9270303
64. A.G. Porter R.U. Janicke Emerging roles of caspase-3 in apoptosis Cell Death Differ. 1999 6 99 04 10.1038/sj.cdd.4400476 1:CAS:528:DyaK1MXhs1Cns74%3D 10200555
65. R.U. Janicke M.L. Sprengart M.R. Wati A.G. Porter Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis J. Biol. Chem. 1998 273 9357 9360 10.1074/jbc.273.16.9357 1:CAS:528:DyaK1cXivVOku7w%3D 9545256
66. M. Woo R. Hakem M.S. Soengas et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes Genes Dev. 1998 12 806 819 10.1101/gad.12.6.806 1:CAS:528:DyaK1cXivV2qsrc%3D 9512515 316633
67. J.L. Gooch D. Yee Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells Cancer Lett. 1999 144 31 37 10.1016/S0304-3835(99)00208-6 1:CAS:528:DyaK1MXltlCku7k%3D 10503875
68. K. Orth A.M. Chinnaiyan M. Garg C.J. Froelich V.M. Dixit The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A J. Biol. Chem. 1996 271 16443 16446 10.1074/jbc.271.28.16443 1:CAS:528:DyaK28Xkt1eqtbo%3D 8663580
69. M. Germain E.B. Affar D. D’Amours V.M. Dixit G.S. Salvesen G.G. Poirier Cleavage of au-tomodified poly(ADP-ribose) polymerase during apoptosis—Evidence for involvement of caspase-7 J. Biol. Chem. 1999 274 28379 28384 10.1074/jbc.274.40.28379 1:CAS:528:DyaK1MXmsFWgtbw%3D 10497198
70. D. Dittmer S. Pati G. Zambetti et al. Gain of function mutations in p53 Nat. Genet. 1993 4 42 46 10.1038/ng0593-42 1:CAS:528:DyaK3sXkt1ajsbo%3D 8099841
71. P.K. Liu E. Kraus T.A. Wu L.C. Strong M.A. Tainsky Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations Oncogene 1996 12 2267 2278 8649766 2719722 1:CAS:528:DyaK28XjvFCmt7s%3D
72. S.W. Lowe S. Bodis A. McClatchey et al. p53 status and the efficacy of cancer therapy in vivo Science 1994 266 807 810 10.1126/science.7973635 1:CAS:528:DyaK2MXitVGgt7w%3D 7973635
73. S.W. Lowe Cancer therapy and p53 Curr. Opin. Oncol. 1995 7 547 553 10.1097/00001622-199511000-00013 1:CAS:528:DyaK28XisFylsrg%3D 8547404
74. K. Nakano T. Mizuno Y. Sowa et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line J. Biol. Chem. 1997 272 22199 22206 10.1074/jbc.272.35.22199 1:CAS:528:DyaK2sXlslOgt7Y%3D 9268365
75. S.Y. Archer S. Meng A. Shei R.A. Hodin p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells Proc.Natl. Acad. Sci. U.S.A. 1998 95 6791 6796 10.1073/pnas.95.12.6791 1:CAS:528:DyaK1cXjslynur8%3D 9618491 22637
76. Y. Sowa T. Orita S. Minamikawa et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites Biochem. Biophy. Res. Commun. 1997 241 142 150 10.1006/bbrc.1997.7786 1:CAS:528:DyaK2sXotVWitb0%3D
77. L.C. Sambucetti D.D. Fischer S. Zabludoff et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects J. Biol. Chem. 1999 274 34940 34947 10.1074/jbc.274.49.34940 1:CAS:528:DyaK1MXnvFyrtrY%3D 10574969
78. M.F. Olson R. Marais Ras protein signalling Semin. Immunol. 2000 12 63 73 10.1006/smim.2000.0208 1:CAS:528:DC%2BD3cXhvFartrk%3D 10723799
79. K. Katagiri S. Hattori S. Nakamura T. Yamamoto T. Yoshida T. Katagiri Activation of Ras and formation of GAP complex during TPA-induced monocytic differentiation of HL-60 cells Blood 1994 84 1780 1789 7521689 1:CAS:528:DyaK2MXotVamsQ%3D%3D
80. M. Adachi R. Ryo A. Yoshida et al. Induction of smg p21/rap1A p21/krev-1 p21 gene expression during phorbol ester-induced differentiation of a human megakaryocytic leukemia cell line Oncogene 1992 7 323 329 1549353 1:CAS:528:DyaK38XhvFWrtb4%3D
81. L.H. Young X. Yang J.M. Voigt Alteration of gene expression in rat mammary tumors induced by N-methyl-N-nitrosourea Mol. Carcinog. 1996 15 251 260 10.1002/(SICI)1098-2744(199604)15:4<251::AID-MC2>3.0.CO;2-J 1:CAS:528:DyaK28XisVOlsLY%3D 8634083
82. X. Yang L.H. Young J.M. Voigt Expression of a vitamin D-regulated gene (VDUP-1) in untreated- and MNU-treated rat mammary tissue Breast Cancer Res. Treat. 1998 48 33 44 10.1023/A:1005929714900 1:CAS:528:DyaK1cXitFehsrg%3D 9541187
83. Y. Tagaya Y. Maeda A. Mitsui et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction EMBO J. 1989 8 757 764 2785919 400872 1:CAS:528:DyaK3cXlvVWg 10.1002/j.1460-2075.1989.tb03436.x
84. D.J. Kwiatkowski Predominant induction of gelsolin and actin-binding protein during myeloid differentiation J. Biol. Chem. 1988 263 13857 13862 2843540 1:CAS:528:DyaL1cXls1OqtbY%3D
85. M. Tanaka A. Sazawa N. Shinohara et al. Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice Cancer Gene Ther. 1999 6 482 487 10.1038/sj.cgt.7700073 1:CAS:528:DyaK1MXmtlOgsL0%3D 10505859
86. Y. Hoshikawa H.J. Kwon M. Yoshida S. Horinouchi T. Beppu Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines Exp. Cell Res. 1994 214 189 197 10.1006/excr.1994.1248 1:CAS:528:DyaK2cXlslamtbY%3D 8082721
87. Y.B. Kim K.H. Lee K. Sugita M. Yoshida S. Horinouchi Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase Oncogene 1999 18 2461 2470 10.1038/sj.onc.1202564 1:CAS:528:DyaK1MXjtV2murs%3D 10229197
88. A. Saito T. Yamashita Y. Mariko et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors Proc. Natl. Acad. Sci. U.S.A. 1999 96 4592 4597 10.1073/pnas.96.8.4592 1:CAS:528:DyaK1MXjs1ylsbk%3D 10200307 16377
89. X. Nan H.H. Ng C.A. Johnson et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 1998 393 386 389 10.1038/30764 1:CAS:528:DyaK1cXjsFKgurc%3D 9620804
90. P.L. Jones G.J. Veenstra P.A. Wade et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription Nat. Genet. 1998 19 187 191 10.1038/561 1:CAS:528:DyaK1cXls1Cqsbg%3D 9620779